EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors

Sophia Golec, Anand Vaidya iD, Bertram Pitt iD, Iris Z Jaffe iD

Circulation Research · 17.07.2026 · 139 (3)

DOI: 10.1161/circresaha.126.327593 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Circulation Research, erschienen am 17.07.2026. Verfasst von Sophia Golec und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Tufts Medical Center, Boston, MA (S.G., I.Z.J.). Hauptthemen laut MEDLINE: Mineralocorticoids, Hypertension, Mineralocorticoid Receptor Antagonists, Cytochrome P-450 CYP11B2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension prevalence rises dramatically with advancing age, is not well controlled with current therapy, and contributes substantially to cardiovascular, renal, and neurological disorders that are common in the elderly. The renin-angiotensin-aldosterone system is a hormonal pathway with multiorgan involvement critical to controlling blood pressure. The production of the steroid hormone aldosterone and the activation state of its MR (mineralocorticoid receptor) are important clinical targets for hypertension treatment and cardiorenal disease prevention. This review summarizes studies demonstrating that aging is associated with (1) dysregulation of adrenal aldosterone production by autonomous aldosterone-producing adrenal cells and, when comorbid with obesity, by factors released from adipose tissue that promote adrenal aldosterone production; (2) increased expression of the MR due to oxidative stress–activated and inflammation-activated transcription factors; and (3) aldosterone-independent MR activation by oxidative stress–activated Rac1 (Ras-related C3 botulinum toxin substrate 1), angiotensin II signaling, and declining expression of the cortisol-inactivating enzyme 11β-HSD2 (11-beta-hydroxysteroid dehydrogenase type 2). Together, these data support the concept that elderly individuals are at high risk for mineralocorticoid-driven hypertension and associated cardiovascular, renal, and neurological disease. The review further describes the different classes of agents that inhibit this pathway, including traditional steroidal MR antagonists, newer nonsteroidal MR antagonists, and aldosterone synthase inhibitors, comparing their modes of action. The steroidal MR antagonists and nonsteroidal MR antagonists have different degrees of MR selectivity and potency, yet they all block MR activation by aldosterone, cortisol, and ligand-independent mechanisms. The aldosterone synthase inhibitors block aldosterone production in the adrenal gland and attenuate aldosterone-mediated MR effects. All 3 drug classes raise potassium proportional to the degree of renal MR inhibition. Trials are summarized showing efficacy of the new agents in reducing MR activation, aldosterone production, blood pressure, and adverse cardiorenal outcomes. Head-to-head studies in older individuals are needed to determine the relative efficacy of aldosterone synthase versus MR inhibition for blood pressure control to improve outcomes in the elderly and very old.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MineralocorticoidsHypertensionMineralocorticoid Receptor AntagonistsCytochrome P-450 CYP11B2Enzyme InhibitorsAgingAge FactorsHumansAldosteroneAdrenal GlandsObesityOxidative Stress

Stichwörter der Autor:innen

agingaldosteroneblood pressurehypertensionreceptors, mineralocorticoid

Substanzen

MineralocorticoidsMineralocorticoid Receptor AntagonistsCytochrome P-450 CYP11B2Enzyme InhibitorsAldosterone

Autor:innen und Institutionen

  • Division of Cardiology, Tufts Medical Center, Boston, MA (S.G., I.Z.J.).
  • Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Metabolism, Mass General Brigham, Harvard Medical School, Boston, MA (A.V.).
  • Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, MI (B.P.).
  • Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA (I.Z.J.).

ORCID-Profile: Anand Vaidya, Bertram Pitt, Iris Z Jaffe

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Golec, S., Vaidya, A., Pitt, B., & Jaffe, I. Z. (2026). Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors. Circulation Research, 139(3). https://doi.org/10.1161/circresaha.126.327593

Vancouver

Golec S, Vaidya A, Pitt B, Jaffe IZ. Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors. Circulation Research. 2026;139(3). doi:10.1161/circresaha.126.327593

BibTeX
@article{Golec2026,
  author = {Golec, Sophia and Vaidya, Anand and Pitt, Bertram and Jaffe, Iris Z},
  title = {Mechanisms for Mineralocorticoid-Driven Age-Related Hypertension: Potential Therapeutic Role of Mineralocorticoid Receptor Antagonists and Aldosterone Synthase Inhibitors},
  journal = {Circulation Research},
  year = {2026},
  volume = {139},
  number = {3},
  doi = {10.1161/circresaha.126.327593}
}
Kostenlos starten →